Oppenheimer Asset Management Inc. Sells 21,543 Shares of Boston Scientific Corporation $BSX

Key Points

• Oppenheimer Asset Management reduced its stake in Boston Scientific (BSX) by 10.3% in Q4, selling 21,543 shares and ending the quarter with 186,886 shares valued at about $17.82 million.
• Analyst views are mixed: several firms have trimmed price targets recently, but the consensus rating is a Moderate Buy with an average price target of $93.91 and the majority of analysts still at Buy.
• Boston Scientific modestly beat the latest quarter (EPS $0.80, revenue $5.20B) and provided Q2 and FY2026 EPS guidance, while facing legal overhang from class‑action filings and notable insider selling by the CEO (160,901 shares).

Oppenheimer Asset Management Inc. decreased its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 10.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 186,886 shares of the medical equipment provider's stock after selling 21,543 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Boston Scientific were worth $17,820,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Financial Consulate Inc. bought a new stake in Boston Scientific during the third quarter worth $25,000. Murphy & Mullick Capital Management Corp grew its holdings in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock worth $25,000 after buying an additional 170 shares in the last quarter. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter worth $26,000. United Community Bank boosted its position in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 147 shares during the last quarter. Finally, Colonial Trust Co SC boosted its position in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 231 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on BSX shares. TD Cowen cut their price objective on Boston Scientific from $115.00 to $100.00 and set a "buy" rating on the stock in a research report on Monday, February 2nd. Citigroup cut their price objective on Boston Scientific from $94.00 to $87.00 and set a "buy" rating on the stock in a research report on Tuesday, April 7th. Argus raised Boston Scientific to a "strong-buy" rating in a research report on Thursday, February 26th. JPMorgan Chase & Co. cut their price objective on Boston Scientific from $135.00 to $100.00 and set an "overweight" rating on the stock in a research report on Thursday, February 5th. Finally, BTIG Research dropped their price target on Boston Scientific from $90.00 to $80.00 and set a "buy" rating on the stock in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific has an average rating of "Moderate Buy" and a consensus price target of $93.91.

Boston Scientific Stock Performance

Shares of BSX opened at $57.69 on Friday. The stock's 50-day simple moving average is $67.06 and its 200 day simple moving average is $84.72. The stock has a market capitalization of $85.74 billion, a price-to-earnings ratio of 24.14, a price-to-earnings-growth ratio of 1.05 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific Corporation has a 52-week low of $56.05 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts' expectations of $5.19 billion. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.The firm's quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts forecast that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: New clinical data and procedure adoption: A Reuters note highlighted that a procedure using a Boston Scientific device outperformed drug therapy for a heart‑rhythm indication, supporting device demand and reimbursement relevance. This is a clear product/market tailwind if adoption continues. Procedure using Boston Scientific device tops medication
• Positive Sentiment: Supportive TV commentary: Jim Cramer said he thinks Boston Scientific "can come back," a sentiment that can boost retail interest and short‑term buying flows. Jim Cramer on Boston Scientific
• Positive Sentiment: Institutional buying signal: Lone Pine Capital (Stephen Mandel) opened a new position, signaling selective hedge‑fund interest in BSX. Large manager activity can be supportive for the stock if it continues. Stephen Mandel opens new position
• Neutral Sentiment: Investor attention piece: Zacks flagged BSX as drawing investor attention, a sign of increased search/interest but not necessarily directional news. Monitor volume and follow‑through. Zacks: BSX attracting investor attention
• Neutral Sentiment: Ticker confusion: A GlobeNewswire item about Belo Sun TSX: BSX appears in feeds — note this is a different company and unrelated to Boston Scientific NYSE: BSX. Don’t conflate the two. Belo Sun Provides Update (unrelated ticker)
• Neutral Sentiment: Market commentary roundup: Aggregated articles (MSN/Yahoo) are weighing bullish vs bearish views; these are useful for sentiment tracking but contain no single material disclosure. MSN: Wall Street bullish or bearish?
• Negative Sentiment: Class‑action filings and lead‑plaintiff deadline (May 4): Multiple law firms and plaintiff notices allege disclosure issues around U.S. electrophysiology sales and invite claims—this increases legal overhang and potential settlement risk. Monitor filings and reserve/expense guidance. Securities fraud lawsuit alert
• Negative Sentiment: Analyst downgrades and lower targets: Daiwa cut BSX to "hold" and at least one outlet reports an ~11% cut to the price target — these reduce near‑term analyst support and can pressure sentiment. Daiwa downgrade / analyst action
• Negative Sentiment: Fund selling and estimate cuts: Polen Capital disclosed it sold its stake citing competition concerns, and Erste Group trimmed FY2026/27 EPS forecasts — both items point to investor wariness on competitive pressure and margin/earnings outlook. Polen sold stake

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company's stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.